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941Intravenous antiplatelet agents such as IIb/IIIa inhibitors or can-
grelor may offer a bridge for this initial delay of antiplatelet action
of ticagrelor administered as either a standard or double LD.
Alternatively, earlier (i.e., pre-hospital) administration of ticagrelor
may lead to better platelet inhibition during primary PCI. The
clinical utility of this strategy is being tested by the ongoing
ATLANTIC study (NCT01347580).
Our study was not randomized; however, demographic and
clinical characteristics were balanced between patients treated with
a double and a standard LD. Furthermore, a propensity score was
used to adjust for potential biases. The study was purely pharma-
codynamic, not allowing any conclusions on clinical outcome. We
used only 1 method for platelet function testing; however, Ver-
ifyNow is the most validated method and correlates well with light
transmittance aggregometry. The lack of pharmacokinetic data
does not allow elucidation of the exact mechanisms responsible for
the double LD delayed onset of action of ticagrelor. In this small
study, a double LD was well tolerated, which is consistent with
a previous report (5).
In patients with STEMI undergoing primary PCI, doubling the
LD of ticagrelor is not accompanied by a faster than standard dose
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APPENDIX
For supplementary tables, please see the online version of this article.Letters to the EditorTroponin Testing for Detection
of Acute Myocardial Infarction in
Skeletal Muscle Disease Patients
Follow the Guidelines
In a recent letter to the editor of the Journal (1), Rittoo describes
what he calls a “fundamental error” in the guidance documents on
the diagnosis of acute myocardial infarction (AMI), namely, in the
universal deﬁnition of AMI (2) and the expert consensus (3), with
potential implications for the detection of AMI during increased
skeletal muscle repair or disease events. In particular, Rittoo infers
from 3 references (4–6), with overlapping authorship, that diseased
skeletal muscle may re-express cardiac troponin T (cTnT), but not
cTnI, which may then lead to elevated cTnT in serum. The author
further states that the guidance documents wrongly deﬁne eleva-
tions of the marker in the circulation as “virtually diagnostic of
myocardial necrosis.”
In our view, Rittoo’s statements were incorrect and misleading
for several reasons. First, the suspected cardiac (un)speciﬁcity of
cTnT could not be derived from the cited references (4–6). For
example, the ﬁrst study (4) compared different cTnT antibody
generations and concluded that “circulating cTnT or cTnI in either
end-stage renal disease (ESRD) or Duchenne muscular dystrophy
(DMD) patients originates from the heart” (and not from skeletal
muscle), which was in contrast to Rittoo’s interpretation of these
data. In the second cited reference (5), the bands in the Western
blot analyses of DMD had a smaller molecular weight (molecular
mass 33 to 39 kDa) compared with that from heart muscle or
puriﬁed protein, suggesting that different cTnT isoforms were
observed; importantly, it was found that the Roche antibody M7
was not reactive to these smaller cTnT isoforms (7). The different
antibody reactivity therefore illustrates the utmost importance of
including more than 1 antibody for both cTnT and cTnI isoforms
when drawing general conclusions on their cardiac speciﬁcity and
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942eventual smaller fetal or degraded isoforms. It was therefore rather
speculative to use the observations with non-Roche antibodies (5)
to conclude that Roche’s troponin assays were incorrect, as was
done by Rittoo (1). The third reference (6) did not compare cTnI
in diseased skeletal muscle with cTnT, so those comparative
conclusions also appeared speculative (1).
Furthermore, using former antibody generations, the detection
sensitivity for the different cTn isoforms differed up to 100-fold,
also because of different degradation kinetics and complexation of
the isoforms (8–10). A simpliﬁed differentiation between cTnT and
cTnI, such as suggested by Rittoo (1), would thus not address the
reported variability of different cTnI antibodies (11). Also, when
using highly sensitive techniques, such as polymerase chain reaction
(PCR), it could not be excluded that RNA in peripheral blood
might contribute to positive PCR results in tissue analysis (12,13).
Moreover, the references in Rittoo’s letter were not representative
because a more systematic literature search revealed that not only
cTnT, but also cTnI andmRNA for cTnI, were found to be elevated
in diseased skeletal muscle tissue (14,15) and in serum (16–21) of
skeletal muscle disease patients. Therefore, Rittoo’s conclusion that
“chronic injury to skeletal muscle causes the release of cTnT but not
cTnI” was not sufﬁciently supported by data. Neither cTnT nor
cTnI was consistently found to be elevated in regenerating skeletal
muscle (22), so that the source for the occasionally detected cTn
isoforms in diseased skeletal muscle was unclear in general. In other
words, there was no sufﬁcient evidence that 1 of the 2 addressed
troponin isoforms would be more or less cardiac speciﬁc than the
other. Additionally, it also seemed that the absence of other
troponin relevant comorbidities was not adequately ruled out (4–6).
A similarly controversial discussion started in the 1990s on
elevated serum troponin inESRDwhen an improved assay sensitivity
and considerations on different standardizations helped to clarify that
elevated serum cTnT was correlated with risk for cardiac disease and
morbidity (23,24), which then became a helpful predictor ofmortality
in hemodialysis patients as proposed by clinical guidelines (25). Thus,
the question of clinical relevancy is whether a troponin elevation in
skeletalmuscle disease patientsmay be of similar prognostic relevance
in ESRD patients. Accordingly, patients with skeletal muscular
dystrophy are at increased risk of cardiac disease (26).
Second, and most importantly, the guidance documents were not
properly applied in Rittoo’s letter. The guidelines clearly require
additional elements for the diagnosis of AMI beyond a single
elevation of troponin in the circulation. Speciﬁcally, the guidance
documents deliberately require a rise and/or fall of serial troponin,
such as evidenced by a repeated troponin measurement. To date,
such a rise and/or fall has not been documented in skeletal muscle
disease patients in the absence of an AMI. This makes the troponin
T assay clinically useful to detect AMI in patients, disregarding the
eventual presence of rare skeletal muscle diseases.
Similarly, Rittoo’s “fundamental error” accusation toward the
guideline writing committees lacks an adequate scientiﬁc basis and
a proper interpretation of the guidelines. Again, both guidance
documents (2,3) do not propose a single troponin elevation per se
as being indicative for AMI, but instead, a troponin rise and/or fall
and clinical evidence of myocardial ischemia (e.g., symptoms,
electrocardiographic changes, or imaging evidence) (3). These cri-
teria ensure the fundamental differentiation between acute eleva-
tions of troponin in cases of AMI and chronically elevated troponin
levels in other diseases (27).
In conclusion, it is our view that: 1) the cTnT assay is suited to
support the diagnosis of AMI in patients with or without skeletalmuscle disease; and 2) neither the American College of Cardiology
Foundation nor other organizations will need to amend their
recommendations.*André Ziegler, PhD
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Ratio Equivalent to Fractional
Flow Reserve?
We read the paper by Sen et al. (1) with great interest; the study was
designed to explore whether the instantaneous wave-free ratio (iFR)
was an adenosine-free alternative to fractional ﬂow reserve (FFR)
for the assessment of coronary stenosis. Hyperemic stenosis resis-
tance (HSR) was used as a reference standard to determine when
iFR and FFR disagreed as to which index was most representative
of the hemodynamic signiﬁcance of the stenosis. It was concluded
that iFR and FFR had equivalent agreement with classiﬁcation
of coronary stenosis severity by HSR, and the administration of
adenosine did not improve diagnostic categorization. However, we
have several concerns regarding the data the study presented.
First, the well-designed study only investigated 51 vessels, which
signiﬁcantly reduces the reliability of the result. We noticed that in
the 4 lesions of 2 groups (iFR[] and FFR(þ); iFR(þ) and
FFR[]), in which there was disagreement, HSR agreed with FFR
in 1 case (50%) and with iFR in the other case (50%) for each
group, respectively (1). Based on these data, how could we trust
that iFR and FFR were equally representative of the hemodynamic
signiﬁcance of the stenosis rather than an element of serendipity? It
was not convincible that “the proportion (7.7%) is consistent with
clinical populations, the ADVISE Registry (6%), and South
Korean Study (6%), suggesting that the study ﬁndings are consis-
tent with other, larger datasets” (1).
Second, we noted that “using the established ischemic cut-off point
of>0.8 mmHg/cm$s for HSR (2),” a 0.75 cutoff point for FFR was
found to have an optimal diagnostic efﬁciency of 0.96 (1). The cutoff
for HSR was certainly key to the study, which was used to determine
the cutoff of iFR and FFR and dominated the disagreement betweenthem. However, the problem is that there is no evidence of the so-
called “established ischemic cut-off point of >0.8 mm Hg/cm$s for
HSR” in the study by Christou et al (2). What is wrong with that?
Could we just explain it as a mistake? Because we did ﬁnd a paper (3)
to validate a cutoff of >0.8 mm Hg/cm$s for HSR, which was also
cited in the study. If so, we have to know if this was the only paper
(3) to date to determine such a cutoff of HSR without reproduc-
ibility. Furthermore, possible inﬂuences of hemodynamic alterations
(heart rate, aortic pressure, contractility) on HSR have not been
investigated (3).
In summary, it was of great signiﬁcance for the study to clarify
whether iFR was an adenosine-free alternative to FFR, especially
when the VERIFY (Veriﬁcation of Instantaneous Wave-Free Ratio
and Fractional Flow Reserve for the Assessment of Coronary Artery
Stenosis Severity in Everyday Practice) study (4) indicated that iFR
correlates weakly with FFR and was not independent of hyperemia.
However, maybe we should not take the urgency, but the large-sized
algorithm, to clarify the issue.Moreover, it might be advisable to ﬁnd
a well-validated, pressure-and-ﬂow index as a reference standard.Guo-Xin Fan, MD
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Equivalent to Fractional Flow Reserve?
We are honored that Drs. Fan and Xu noticed some differences
between the CLARIFY (Classiﬁcation Accuracy of Pressure-Only
Ratios Against Indices Using Flow Study) (1) and VERIFY
